Lataa...
Clinical implications of mismatch repair deficiency in prostate cancer
Immune checkpoint blockade holds great promise in the treatment of solid tumors but has not yet been approved for use in advanced prostate cancer. This is largely due to the relatively modest response in clinical trials in unselected patients and the lack of available biomarkers to predict clinical...
Tallennettuna:
| Julkaisussa: | Future Oncol |
|---|---|
| Päätekijät: | , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Future Medicine Ltd
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6714067/ https://ncbi.nlm.nih.gov/pubmed/31237441 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/fon-2019-0068 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|